News
Sortina Pharma AB announces official publication of the issued Swedish patent no. 2151469-0
Sortina Pharma AB announces official publication of the issued Swedish patent no. 2151469-0.
Sortina Pharma AB announces the appointment of new members to its Board of Directors
Sortina Pharma AB announces the appointment of new members to its Board of Directors, strengthening the company for acceleration and positioning in the development of world leading anti-Sortilin small molecule therapeutics.
Sortina Pharma - Lifesciencedagen
Sara Rhost presenting Sortina Pharma on Lifesciencedagen. See the presentation (held in swedish).
Sortina Pharma AB has appointed Sara Rhost as CEO
Sara has a doctoral degree in immunology from Gothenburg University and has been managing and driving the sortilin-project from research into product development. She has extensive experience in…
Clinical article: Berger et al 2021 BMC Cancer
Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.
Iscaffpharma and Sortina pharma enter a collaboration agreement to generate cure for cancer
With the agreement that has now been concluded between Iscaffpharma and Sortina Pharma, more effective products to cure aggressive breast cancer can be generated. Sortina Pharma, which is developing…
Research article: Rhost et al., BCR, 2018
Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion.